Loading...
XCSENOVO B
Market cap447bUSD
Dec 20, Last price  
589.20DKK
1D
-20.72%
1Q
-30.68%
Jan 2017
362.66%
Name

Novo Nordisk A/S

Chart & Performance

D1W1MN
XCSE:NOVO B chart
P/E
38.23
P/S
13.77
EPS
15.41
Div Yield, %
0.99%
Shrs. gr., 5y
-1.50%
Rev. gr., 5y
15.74%
Revenues
232.26b
+31.26%
29,233,563,87033,713,685,04038,751,814,80041,888,774,00045,666,120,40051,078,000,00060,776,000,00066,346,000,00078,026,000,00083,572,000,00088,806,000,000107,927,000,000111,780,000,000111,696,000,000111,831,000,000122,021,000,000126,946,000,000140,800,000,000176,954,000,000232,261,000,000
Net income
83.68b
+50.71%
5,048,785,2005,856,397,4206,452,985,2008,535,266,0009,666,004,40010,768,000,00014,403,000,00017,097,000,00021,432,000,00025,184,000,00026,481,000,00034,860,000,00037,925,000,00038,130,000,00038,628,000,00038,951,000,00042,138,000,00047,757,000,00055,525,000,00083,683,000,000
CFO
108.91b
+38.06%
7,644,519,3308,699,492,4007,741,322,0009,997,870,00012,896,921,20015,378,000,00019,679,000,00021,374,000,00022,214,000,00025,942,000,00031,692,000,00038,287,000,00048,314,000,00041,168,000,00044,616,000,00046,782,000,00051,951,000,00055,000,000,00078,887,000,000108,908,000,000
Dividend
Aug 15, 20243.5 DKK/sh
Earnings
Feb 05, 2025

Profile

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
URL
https://www.novonordisk.com/
IPO date
May 17, 1974
Employees
59,337
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
232,261,000
31.26%
176,954,000
25.68%
140,800,000
10.91%
Cost of revenue
129,806,000
103,179,000
82,488,000
Unusual Expense (Income)
NOPBT
102,455,000
73,775,000
58,312,000
NOPBT Margin
44.11%
41.69%
41.41%
Operating Taxes
20,991,000
13,537,000
11,323,000
Tax Rate
20.49%
18.35%
19.42%
NOPAT
81,464,000
60,238,000
46,989,000
Net income
83,683,000
50.71%
55,525,000
16.27%
47,757,000
13.33%
Dividends
(31,767,000)
(25,303,000)
(21,517,000)
Dividend yield
Proceeds from repurchase of equity
(29,924,000)
(24,086,000)
(19,447,000)
BB yield
Debt
Debt current
6,478,000
1,466,000
13,684,000
Long-term debt
26,254,000
28,847,000
17,090,000
Deferred revenue
7,391,000
5,654,000
Other long-term liabilities
189,000
5,452,000
360,000
Net debt
839,000
5,396,000
11,848,000
Cash flow
Cash from operating activities
108,908,000
78,887,000
55,000,000
CAPEX
(38,896,000)
(14,753,000)
(7,385,000)
Cash from investing activities
(43,892,000)
(24,918,000)
(31,605,000)
Cash from financing activities
(63,158,000)
(51,797,000)
(25,493,000)
FCF
69,425,000
59,972,000
42,133,000
Balance
Cash
30,230,000
23,574,000
17,485,000
Long term investments
1,663,000
1,343,000
1,441,000
Excess cash
20,279,950
16,069,300
11,886,000
Stockholders' equity
106,566,000
83,492,000
70,752,000
Invested Capital
113,751,050
91,561,700
87,861,000
ROIC
79.36%
67.15%
60.44%
ROCE
71.05%
64.32%
55.53%
EV
Common stock shares outstanding
4,494,800
4,544,600
4,606,200
Price
Market cap
EV
EBITDA
111,868,000
81,137,000
64,337,000
EV/EBITDA
Interest
542,000
378,000
2,451,000
Interest/NOPBT
0.53%
0.51%
4.20%